CA BOTANA International Initiates Class II Recall for Benzoyl Peroxide Cream Due to CGMP Deviations
CA BOTANA International initiated a voluntary Class II recall for 470 tubes of Doctor D. Schwab Controlling Cream (Benzoyl Peroxide 2.7%) due to CGMP deviations. This event, impacting distribution across five U.S. states and Puerto Rico, signals critical quality control vulnerabilities for procurement and regulatory teams, necessitating immediate supply chain and compliance review.
CA BOTANA International Initiates Class II Recall for Benzoyl Peroxide Cream Due to CGMP Deviations
CA BOTANA International, Inc., based in San Diego, California, has initiated a voluntary Class II recall for its Doctor D. Schwab Controlling Cream, specifically the Benzoyl Peroxide 2.7% formulation. This recall, identified as D-0186-2026, involves 470 tubes of the 1 FL OZ/30 ML product, bearing NDC: 35192-017-05 and Lot Code D54066, with an expiration date of May 31, 2027. The firm initiated this action on October 10, 2025, with the FDA classifying it on November 26, 2025, and the report date being December 3, 2025. The primary reason cited for this recall is deviations from Current Good Manufacturing Practices (CGMP). For procurement directors, this event necessitates an immediate review of all Benzoyl Peroxide 2.7% product inventories and supply agreements, particularly those involving CA BOTANA International. Regulatory affairs heads must assess the implications of CGMP non-compliance on their own product portfolios and ensure robust quality oversight of all contract manufacturers and raw material suppliers. Supply chain VPs should activate recall protocols to ensure efficient and complete market withdrawal across the affected distribution network.
Navigating CGMP Compliance Risks in Topical Drug Manufacturing
The stated reason for CA BOTANA International's recall—CGMP Deviations—underscores critical vulnerabilities in manufacturing quality systems. While specific details of the deviations are not disclosed, CGMP non-compliance typically indicates failures in areas such as facility controls, equipment maintenance, process validation, quality control testing, or personnel training. For companies involved in the manufacturing or distribution of topical drug products, particularly those containing active pharmaceutical ingredients like Benzoyl Peroxide, this recall serves as a significant warning. A Class II recall, as designated by the FDA, signifies that the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This classification still carries substantial financial, reputational, and regulatory risks. Regulatory affairs teams must proactively audit their internal manufacturing sites and third-party contractors to verify stringent adherence to CGMP standards. Business development executives should recognize the heightened regulatory scrutiny in the dermatology and over-the-counter drug sectors, emphasizing the need for partners with impeccable quality records. Procurement directors must prioritize suppliers with transparent and verifiable quality management systems to mitigate future supply disruptions and compliance risks.
Regional Distribution and Supply Chain Implications of the Recall
The recalled Doctor D. Schwab Controlling Cream was distributed across several key U.S. markets, including California (CA), Colorado (CO), Florida (FL), Puerto Rico (PR), and Washington (WA). This broad distribution pattern means that retailers, distributors, and ultimately consumers in these specific regions are directly impacted by the recall. For supply chain VPs, this necessitates a rapid and effective execution of recall procedures within these geographies. The firm's initial notification method, stated as a 'Letter,' suggests a formal communication approach, but the speed of market withdrawal can vary significantly based on the efficiency of downstream partners. Companies operating within these states, particularly those handling dermatology or cosmetic-pharmaceutical hybrid products, must review their own recall preparedness and communication strategies. Procurement teams should evaluate their inventory management systems to quickly identify and segregate affected lots. Business development executives considering market entry or expansion in these regions should factor in the regulatory landscape and the potential for product quality issues to impact consumer trust and market access. This event highlights the critical need for robust traceability systems from manufacturing to the point of sale, especially for products with a defined shelf life like the Benzoyl Peroxide cream expiring in May 2027.